Journey Medical (DERM) Net Income towards Common Stockholders (2020 - 2026)
Journey Medical filings provide 6 years of Net Income towards Common Stockholders readings, the most recent being -$1.2 million for Q4 2025.
- On a quarterly basis, Net Income towards Common Stockholders fell 178.82% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$11.4 million, a 21.76% increase, with the full-year FY2025 number at -$11.4 million, up 22.08% from a year prior.
- Net Income towards Common Stockholders hit -$1.2 million in Q4 2025 for Journey Medical, up from -$2.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $16.8 million in Q3 2023 to a low of -$21.8 million in Q4 2021.
- Median Net Income towards Common Stockholders over the past 5 years was -$3.9 million (2025), compared with a mean of -$5.2 million.
- Biggest five-year swings in Net Income towards Common Stockholders: plummeted 36810.34% in 2021 and later skyrocketed 266.56% in 2023.
- Journey Medical's Net Income towards Common Stockholders stood at -$21.8 million in 2021, then skyrocketed by 51.07% to -$10.6 million in 2022, then soared by 79.86% to -$2.1 million in 2023, then soared by 173.82% to $1.6 million in 2024, then tumbled by 178.82% to -$1.2 million in 2025.
- The last three reported values for Net Income towards Common Stockholders were -$1.2 million (Q4 2025), -$2.3 million (Q3 2025), and -$3.8 million (Q2 2025) per Business Quant data.